



# Department of Health

KATHY HOCHUL  
Governor

JAMES V. McDONALD, MD, MPH  
Commissioner

JOHANNE E. MORNE, MS  
Executive Deputy Commissioner

August 22, 2025

RE: Clarification #3 for Measurement Year (MY) 2025 Updates

Dear Colleague,

This letter contains information about the MY2025 Technical Specifications, the NYS MY2025 QARR List of Required Measures (Table1), and the MY2025 PLD File Specifications (PDF). The files are posted on our Managed Care [Information for Health Plans](#) page. The revised specifications should be used in the plans' processing for MY2025 QARR.

This clarification includes the following changes made to the MY2025 QARR reporting requirements.

Change Version	Version Date	Section(s) Changed	Change Summary
3	8/22/2025	MY2025 Technical Specifications	<ol style="list-style-type: none"><li>1. NYS Measure - <b><u>Continued Engagement in Substance Use Disorder (SUD) Treatment (CET)</u></b> specifications have been updated MAT dispensing guidelines.</li><li>2. NYS Measure - <b><u>Use of Pharmacotherapy for Alcohol Use or Dependence (POA)</u></b> – denominator specifications have been updated.</li></ol>
		MY2025 Table 1: QARR List of Required Measures	<ol style="list-style-type: none"><li>1. <b><u>Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO)</u></b> and <b><u>International Normalized Ratio Monitoring for Individuals on Warfarin (INR)</u></b> – removed as a reporting requirement for Qualified Health Plans (QHP)</li></ol>
		Patient-Level Detail File (PLD) MY2025	<p><b>Commercial Line of Business:</b></p> <ol style="list-style-type: none"><li>1. <b><u>Social Need Screening and Intervention (SNS-E)</u></b> Updated measurement period to January 1–December 31 to align with HEDIS specifications.</li></ol> <p><b>Medicaid Line of Business:</b></p> <ol style="list-style-type: none"><li>1. <b><u>Development Screening (DEV-N)</u></b> and <b><u>Documented Assessment After Mammogram (DBM-E)</u></b> - Rows 237-241 labels and field definitions updated to match measure short name and description. Remaining numbering has been updated accordingly.</li><li>2. <b><u>Social Need Screening and Intervention (SNS-E)</u></b> Updated measurement period to January 1–December 31 to align with HEDIS specifications.</li></ol> <p><b>Exchange/Marketplace Line of Business:</b></p> <ol style="list-style-type: none"><li>1. <b><u>Childhood Immunization Status Electronic (CIS-E)</u></b> and <b><u>Colorectal Cancer Screening (COL-E)</u></b> - Rows 159-162 labels and field definitions updated to match measure short name and description. Remaining numbering has been updated accordingly.</li></ol>

Change Version	Version Date	Section(s) Changed	Change Summary
			<ol style="list-style-type: none"> <li>2. <b><u>Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO)</u></b> and <b><u>International Normalized Ratio Monitoring for Individuals on Warfarin (INR)</u></b> - Removed as a reporting requirement for Qualified Health Plans (QHP). Remaining numbering has been updated accordingly.</li> <li>3. <b><u>Social Need Screening and Intervention (SNS-E)</u></b> Updated measurement period to January 1–December 31 to align with HEDIS specifications.</li> </ol>

If there are any questions about the above edits, or if you find issues or have concerns with the MY2025 Technical Specifications manual or other documents, please email [nysqarr@health.ny.gov](mailto:nysqarr@health.ny.gov).

Sincerely,

Paloma Luisi, MPH  
 Director, Bureau of Quality Measurement & Evaluation  
 Center for Applied Research and Evaluation  
 Office of Health Services Quality and Analytics

CC: R. Josberger  
 E. Nichols  
 C. Fan